Blood test can predict lung cancer 5 years before diagnosis

Scientists have discovered warning signals in the blood that may predict the risk of lung cancer more than five years before a formal diagnosis is made. This breakthrough offers a potential path toward tackling one of the deadliest forms of cancer by identifying high-risk individuals much earlier than current methods allow.

A New Frontier in Risk Assessment

Published in the journal ‘Cell’, the study identified a specific 14-protein blood signature. This signature predicted lung cancer risk a median of 5.6 years before diagnosis.

Researchers reached these findings by analysing health data and blood samples from over 48,000 participants within the UK Biobank. The results were further validated across eight international cohorts involving more than 2,000 lung cancer cases.

Did You Know? In India, lung cancer cases are projected to increase from approximately 63,700 in 2015 to more than 81,000 by 2025, with 80-85% of patients currently diagnosed at an advanced stage.

Combining Proteins and Patient History

The predictive model does not rely on proteins alone. It combines the 14-protein signature with factors such as age, smoking history and chronic lung disease to predict risk more accurately than existing models.

This approach suggests that the protein signature is elevated not only in smokers but also in individuals exposed to particulate air pollution. This finding is particularly significant for regions where air pollution is a growing public health concern.

Expert Insight: Samantha Carter notes that the shift from detecting an existing tumor to identifying a biological predisposition is a critical distinction. By focusing on risk assessment rather than immediate detection, medical professionals may be able to prioritize definitive screening for those most vulnerable long before the disease manifests.

Understanding the Biological Drivers

The research provides new insights into how lung cancer develops. It suggests that air pollution, cancer-causing mutations, and inflammation driven by the immune molecule IL-1β may converge on pathways that promote the formation of tumors.

Dr. Abhishek Shankar, a radiation oncologist at AIIMS Delhi, emphasizes that this tool should be viewed as a risk-assessment mechanism. He notes that while it does not detect a tumor, it identifies people at higher risk who can then undergo more definitive screening.

Future Implications and Validation

While the scientific advance is significant, the protein signatures may need further validation in specific populations, such as those in India, before they can be widely applied.

Dr. David Ahlquist explains the findings of the lung cancer blood test study

If validated, these blood-based risk assessment tools could eventually complement existing screening programs. This may enable earlier monitoring and the implementation of preventive interventions.

Frequently Asked Questions

How far in advance can this blood signature predict lung cancer?

The 14-protein blood signature predicted lung cancer risk a median of 5.6 years before diagnosis.

Is this blood test used to detect existing tumors?

No. According to Dr. Abhishek Shankar, the test is a risk-assessment tool that identifies people at higher risk of developing the disease in the future, rather than detecting an existing tumor.

What factors besides proteins are used to predict risk?

The model combines the protein signature with age, smoking history, and chronic lung disease to improve accuracy.

How do you think early risk-assessment tools could change the way we approach preventive healthcare?

Blood test can predict lung cancer 5 years before diagnosis | India News